Abstract
Eribulin mesylate (eribulin) is a synthetic analogue of the marine-sponge natural product halichondrin B. Eribulin exhibits potent antiproliferative activities against a variety of human cancer cell types in vitro and in vivo, and is used for the treatment of certain patients with advanced breast cancer or liposarcoma who are refractory to other treatments. The antiproliferative effects of eribulin have long been attributed to its antimitotic activities. Unlike other microtubule-targeting agents, eribulin inhibits microtubule polymerization through specific plus end binding, thus interfering with microtubule dynamic instability. Non-mitotic effects of eribulin on tumor biology have also been established in laboratory settings including: tumor vasculature remodeling, increased vascular perfusion, reduced hypoxia, and phenotypic changes involving reversal of epithelial-to-mesenchymal transition (EMT), resulting in reduced capacities for migration, invasion, and seeding lung metastases in experimental models. Preclinical data suggest that increased perfusion following eribulin treatment improves delivery of subsequent drugs. Supporting evidence for eribulin's non-mitotic effects in the clinical setting include increased tumor oxyg...Continue Reading
Citations
Jun 5, 2019·Expert Opinion on Investigational Drugs·Marco TagliamentoAngela Alama
Sep 5, 2019·Cells·Wei WenJohn H Yim
Dec 21, 2019·Future Oncology·Anna PaioliAlessandra Longhi
Mar 12, 2020·Cancers·Claudio VernieriFilippo de Braud
Nov 30, 2019·International Journal of Molecular Sciences·Olga MéndezJosep Villanueva
May 21, 2019·Expert Opinion on Drug Safety·Jose Manuel Perez-Garcia, Javier Cortes
Mar 21, 2019·Future Oncology·Joyce O'ShaughnessyKevin Kalinsky
Jul 3, 2019·Cancers·Sara El-SahliSheng Liu
Apr 15, 2020·Cancers·Fabienne SchochterLisa Wiesmüller
Jan 18, 2020·International Journal of Molecular Sciences·Takaaki MasudaHiroaki Ueo
Jul 10, 2020·Scientific Reports·Joyce O'ShaughnessyTakayuki Ueno
Nov 4, 2020·Planta medica·Diego V WilkeLeticia V Costa-Lotufo
Nov 20, 2020·Bioorganic & Medicinal Chemistry Letters·Jana WaltemateHelge Prinz
Dec 17, 2020·Cancers·Hara PolioudakiPanayiotis A Theodoropoulos
Mar 3, 2021·Cancer Medicine·Tingting WenShucheng Hua
Feb 19, 2021·ESMO Open·C De AngelisG Arpino
Feb 25, 2020·Anti-cancer Agents in Medicinal Chemistry·Sombeer SharmaArun K Sharma
Jun 9, 2021·NPJ Breast Cancer·Leticia De Mattos-ArrudaCarlos Caldas
May 18, 2021·Bioactive Materials·Mei-Chen WanLi-Na Niu
Jun 27, 2021·Biochemical Genetics·Xuedan LaiZhou Lin
Jun 18, 2021·Frontiers in Immunology·Jonathan GoldbergJennifer L Guerriero
Mar 6, 2019·Journal of Natural Products·Roma KaulSusan L Mooberry
Nov 18, 2020·Journal of Medicinal Chemistry·Ying-Jie CuiZhao-Peng Liu
Apr 20, 2020·Chemotherapy·Ayako UenoShoichiro Ohtani
Jul 30, 2021·Anti-cancer Drugs·Shengnan ZhengTingting Yu